Astria Therapeutics, Inc. (ATXS)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
ATXS Insider Trading Activity
ATXS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $135,939 | 1 | 100 |
Related Transactions
| Morabito Christopher | Chief Medical Officer | 0 | $0 | 1 | $135,939 | $-135,939 |
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, …
Insider Activity of Astria Therapeutics, Inc.
Over the last 12 months, insiders at Astria Therapeutics, Inc. have bought $0 and sold $135,939 worth of Astria Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Astria Therapeutics, Inc. have bought $17.2M and sold $123,652 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,481,350 shares for transaction amount of $30M was made by PERCEPTIVE ADVISORS LLC (director) on 2024‑02‑01.
List of Insider Buy and Sell Transactions, Astria Therapeutics, Inc.
| 2024-04-01 | Sale | Morabito Christopher | Chief Medical Officer | 10,000 0.0183% | $13.59 | $135,939 | -27.83% | |
| 2024-02-01 | PERCEPTIVE ADVISORS LLC | director | 2.48M 5.6893% | $12.09 | $30M | -19.99% | ||
| 2024-01-29 | Sale | Morabito Christopher | Chief Medical Officer | 9,200 0.0208% | $11.15 | $102,552 | -8.93% | |
| 2024-01-26 | Sale | Morabito Christopher | Chief Medical Officer | 800 0.0022% | $11.02 | $8,812 | +2.98% | |
| 2023-12-21 | PERCEPTIVE ADVISORS LLC | director | 740,000 2.0257% | $6.20 | $4.59M | +77.37% | ||
| 2023-10-16 | PERCEPTIVE ADVISORS LLC | director | 1.07M 3.9128% | $6.51 | $7M | +56.68% | ||
| 2022-12-19 | PERCEPTIVE ADVISORS LLC | director | 908,265 6.1619% | $11.01 | $10M | -11.17% | ||
| 2021-11-19 | Komjathy Andrew | Chief Commercial Officer | 100 0.0008% | $6.70 | $670 | -6.97% | ||
| 2015-06-30 | SVLSF V, LLC | 10 percent owner | 391,090 2.5125% | $12.00 | $4.69M | -41.69% | ||
| 2015-06-30 | GALAKATOS NICHOLAS | 376,695 2.4201% | $12.00 | $4.52M | -41.69% | |||
| 2015-06-30 | Clarus Lifesciences II, L.P. | 10 percent owner | 376,695 2.4201% | $12.00 | $4.52M | -41.69% | ||
| 2015-06-30 | MedImmune Ventures, Inc. | 10 percent owner | 223,439 1.4355% | $12.00 | $2.68M | -41.69% | ||
| 2015-06-30 | Laufer Ron | 223,439 1.4355% | $12.00 | $2.68M | -41.69% | |||
| 2015-06-30 | George Jean | director | 258,776 1.6625% | $12.00 | $3.11M | -41.69% |
Insider Historical Profitability
| PERCEPTIVE ADVISORS LLC | director | 4873721 8.6361% | $31.44M | 4 | 0 | +25.72% |
| SVLSF V, LLC | 10 percent owner | 2798528 4.9589% | $18.05M | 1 | 0 | |
| GALAKATOS NICHOLAS | 2752488 4.8773% | $17.75M | 1 | 0 | ||
| Clarus Lifesciences II, L.P. | 10 percent owner | 2752488 4.8773% | $17.75M | 1 | 0 | |
| MedImmune Ventures, Inc. | 10 percent owner | 1632652 2.893% | $10.53M | 1 | 0 |
Historical Insider Profitability vs. Competitors
$109,415,500 | 33 | 18.13% | $353.41M | |
$41,446,394 | 27 | 12.91% | $340.18M | |
$14,865,077 | 18 | -28.56% | $389.16M | |
$276,750,010 | 16 | -7.95% | $385.21M | |
$3,232,510 | 15 | -2.42% | $328.58M |
ATXS Institutional Investors: Active Positions
| Increased Positions | 70 | +70.71% | 6M | +9.95% |
| Decreased Positions | 40 | -40.4% | 4M | -6.24% |
| New Positions | 27 | New | 3M | New |
| Sold Out Positions | 17 | Sold Out | 1M | Sold Out |
| Total Postitions | 129 | +30.3% | 59M | +3.71% |
ATXS Ownership Change vs Market
Institutional Investor Ownership
| Fmr Llc | $50,385.00 | 13.97% | 7.82M | +1,454 | +0.02% | 2024-12-31 |
| Perceptive Advisors Llc | $41,766.00 | 11.58% | 6.49M | 0 | 0% | 2024-12-31 |
| Ra Capital Management, L.P. | $32,878.00 | 9.12% | 5.11M | 0 | 0% | 2024-12-31 |
| Vestal Point Capital, Lp | $26,919.00 | 7.46% | 4.18M | +180,000 | +4.5% | 2024-12-31 |
| Blackrock, Inc. | $25,096.00 | 6.96% | 3.9M | +397,387 | +11.36% | 2024-12-31 |
| Fairmount Funds Management Llc | $22,889.00 | 6.35% | 3.55M | 0 | 0% | 2024-12-31 |
| Fcpm Iii Services B.V. | $18,499.00 | 5.13% | 2.87M | +3M | New | 2024-12-31 |
| Tcg Crossover Management, Llc | $17,786.00 | 4.93% | 2.76M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $17,242.00 | 4.78% | 2.68M | +41,833 | +1.59% | 2024-12-31 |
| Vr Adviser, Llc | $15,825.00 | 4.39% | 2.46M | -1M | -28.95% | 2024-12-31 |